Cell Rep Med 2022 Jun;3(6):100664
University of California, San Francisco, Department of Hematology Oncology and Surgery, Helen Diller Comprehensive Cancer Center, San Francisco, CA 94143, USA; University of California, San Francisco, Department of Surgery and Helen Diller Comprehensive Cancer Center, San Francisco, CA 94143, USA. Electronic address:
First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.. Read More